Drugs Made In America Acquisition II Corp.
corporate_fare Company Profile
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is a publicly traded company in the Real Estate & Construction sector. Wiseek has independently scored 10 items for DMII at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for DMII spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- SPAC Proposes $600M Alpha AI Biotech Deal; Investor Adds $250K Convertible Funding
- SPAC Flags Going Concern, Material Weakness, and 35% Discount Convertible Notes
- SPAC DMII Posts $4.34M Net Income in Q1 2026, Reversing Prior Loss
- Company Discloses Material Weakness in Internal Controls, Reaffirms Going Concern
- DMII Formalizes CEO & CFO Compensation with Significant Equity Grants Amid Cash Flow Constraints
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 96,992 shares in DMII as of the October 30, 2026 settlement, a 12.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 24.1% of DMII volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.